Evidence based treatment in cardiology:
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Buch |
| Sprache: | English German |
| Veröffentlicht: |
Bremen [u.a.]
UNI-MED-Verl.
2009
|
| Ausgabe: | 1. ed. |
| Schriftenreihe: | UNI-MED science
|
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | 358 S. Ill., zahlr. graph. Darst. |
| ISBN: | 9783837411737 9781848151505 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV035773020 | ||
| 003 | DE-604 | ||
| 005 | 20091016 | ||
| 007 | t | ||
| 008 | 091015s2009 ad|| |||| 00||| eng d | ||
| 020 | |a 9783837411737 |9 978-3-8374-1173-7 | ||
| 020 | |a 9781848151505 |9 978-1-8481-5150-5 | ||
| 035 | |a (OCoLC)506487518 | ||
| 035 | |a (DE-599)GBV609690949 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 1 | |a eng |h ger | |
| 049 | |a DE-19 | ||
| 082 | 0 | |a 616.1206 |2 22/ger | |
| 100 | 1 | |a Strödter, Dietrich |e Verfasser |0 (DE-588)108228061 |4 aut | |
| 245 | 1 | 0 | |a Evidence based treatment in cardiology |c [Dietrich Strödter ; Frans Santosa] |
| 250 | |a 1. ed. | ||
| 264 | 1 | |a Bremen [u.a.] |b UNI-MED-Verl. |c 2009 | |
| 300 | |a 358 S. |b Ill., zahlr. graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 0 | |a UNI-MED science | |
| 650 | 0 | 7 | |a Therapie |0 (DE-588)4059798-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Herzkrankheit |0 (DE-588)4024663-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Evidenz-basierte Medizin |0 (DE-588)4543414-1 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Herzkrankheit |0 (DE-588)4024663-2 |D s |
| 689 | 0 | 1 | |a Therapie |0 (DE-588)4059798-2 |D s |
| 689 | 0 | 2 | |a Evidenz-basierte Medizin |0 (DE-588)4543414-1 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Santosa, Frans |e Verfasser |0 (DE-588)113400969 |4 aut | |
| 856 | 4 | 2 | |m DNB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=018632680&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-018632680 | ||
Datensatz im Suchindex
| _version_ | 1804140703759990784 |
|---|---|
| adam_text | CONTENTS EVIDENCE-BASED MEDICINE 21 1.1. DEFINITION AND IMPORTANCE 21
1.1.1. RATIONAL AND EFFICIENT MEDICINE 21 1.1.2. AIMS OF EVIDENCE-BASED
MEDICINE 22 1.2. SOURCES OF EVIDENCE-BASED MEDICINE 23 1.2.1. HIERARCHY
OF SCIENTIFIC EVIDENCE 23 1.3. TERMS RELATING TO RISK REDUCTION 23
1.3.1. THE RELATIVE RISK REDUCTION (RRR) 24 1.3.2. THE ABSOLUTE RISK
REDUCTION (ARR) 24 1.3.3. NUMBER NEEDED TO TREAT (NNT) 24 1.3.4. THE NNT
APPLIED TO THE SAME TIME PERIOD 25 1.3.5. CALCULATION FOR PERSON-YEARS
25 1.3.6. SURVIVAL GAIN 25 1.4. A CLASS EFFECT IN THE CASE OF
BENEFIT/HARM? 26 1.5. PREVENTIVE CARDIOLOGY 26 1.6. PROGRAMME OF THE
BOOK*EVIDENCE-BASED TREATMENT IN CARDIOLOGY 27 1.7. REFERENCES 27 THE
TREATMENT OF HYPERTENSION 28 2.1. DEFINITION AND CLINICAL SIGNIFICANCE
28 2.2. SYSTOLIC VERSUS DIASTOLIC BLOOD PRESSURE AS A PREDICTOR OF
PROGNOSIS 31 2.2.1. SYSTOLIC BLOOD PRESSURE 31 2.2.2. PULSE PRESSURE 32
2.2.3. SYSTOLIC BLOOD PRESSURE IN PATIENTS WITH TYPE 2 DIABETES 32
2.2.4. CENTRAL AORTIC BLOOD PRESSURE 32 2.3. ISOLATED SYSTOLIC
HYPERTENSION 33 2.4. RISK REDUCTION AS A RESULT OF THE TREATMENT OF
HYPERTENSION 33 2.4.1. TREATMENT OUTCOMES IN MILD/MODERATE HYPERTENSION
33 2.4.1.1. HDFP STUDY 33 2.4.1.2. AUSTRALIAN STUDY 34 2.4.1.3. MRC
STUDY 34 2.4.2. THE META-ANALYSIS BY COLLINS ET AL 34 2.4.3. MODERATE
CARDIAC RISK REDUCTION 34 2.4.4 BIBLIOGRAFISCHE INFORMATIONEN
HTTP://D-NB.INFO/999294199 DIGITALISIERT DURCH 6 CONTENTS 2.6.3. THE
ALLHAT STUDY 41 2.6.3.1. THE DIURETIC AND ALPHA BLOCKER ARM 41 2.6.3.2.
THE CHLORTHALIDONE, AMLODIPINE AND LISINOPRIL ARM 42 2.6.4. THE NORDIL
STUDY 43 2.6.5. THE INSIGHT STUDY 43 2.6.6. BLOOD PRESSURE LOWERING
TREATMENT TRIALISTS COLLABORATION 44 2.6.7. THE HOPE STUDY 45 2.6.8.
THE PROGRESS STUDY 45 2.6.9. THE LIFE STUDY 46 2.6.10. THE ANBP 2 STUDY
47 2.6.11. THE VALUE STUDY 47 2.6.12. ASCOT-BPLA STUDY 48 2.6.13. THE
FEVER STUDY 49 2.6.14. THE CONVINCE STUDY 49 2.6.15. ACE INHIBITORS
VERSUS CALCIUM ANTAGONISTS*A META-ANALYSIS 49 2.6.16. ACE INHIBITORS
VERSUS AT, RECEPTOR BLOCKERS VERSUS A COMBINATION OF BOTH* THE ONTARGET
STUDY 50 2.7. STUDIES ON THE TREATMENT OF THE HYPERTENSIVE DIABETIC
PATIENT 51 2.7.1. THE UKPDS STUDY*BETA-BLOCKER VERSUS CAPTOPRIL 51
2.7.2. THE ABCD STUDY 51 2.7.3. THE FACET STUDY 52 2.7.4. THE PRIME
PROGRAMME 52 2.7.4.1. THE IRMA II STUDY 53 2.7.4.2. THE IDNT STUDY 53
2.7.5. THE RENAAL STUDY 54 2.7.6. THE LEWIS STUDY IN PATIENTS WITH TYPE
1 DIABETES 55 2.7.7. DIABETICS IN THE LIFE STUDY 56 2.7.8. THE ADVANCE
STUDY 56 2.8. INTERVENTION STUDIES IN ISOLATED SYSTOLIC HYPERTENSION
(ISH) 57 2.8.1. THE SHEP STUDY 57 2.8.1.1. RESULTS IN THE OVERALL
POPULATION 57 2.8.1.2. RESULTS OF THE SHEP STUDY IN
NON-INSULIN-DEPENDENT DIABETICS 58 2.8.2. THE SYST-EUR STUDY 58 2.8.2.1.
RESULTS IN THE OVERALL POPULATION 58 2.8.2.2 CONTENTS 7 2.10.4.
NEPHROPROTECTION IN MIXED POPULATIONS 68 2.10.4.1. THE IMPROVE-IT STUDY
68 2.10.4.2. RESULT OF A RECENT META-ANALYSIS 68 2.11. ANTIHYPERTENSIVES
AND SURROGATE PARAMETERS FOR CARDIOVASCULAR END ORGAN DAMAGE 68 2.12.
ANTIHYPERTENSIVES AND THE DEVELOPMENT OF DIABETES 69 2.12.1. DEVELOPMENT
OF DIABETES LESS COMMON 69 2.12.2. HIGHER INCIDENCE OF THE DEVELOPMENT
OF DIABETES 70 2.13. DIFFERENTIATED TREATMENT OF HYPERTENSION 71 2.14.
ANTIHYPERTENSIVE DRUGS 72 2.14.1. CLASSIFICATION OF ANTIHYPERTENSIVE
DRUGS 72 2.14.2. CHARACTERISTICS OF THE ANTIHYPERTENSIVE DRUG CLASSES 72
2.14.2.1. DIURETICS 72 2.14.2.2. BETA-BLOCKERS 74 2.14.2.3. CALCIUM
ANTAGONISTS 75 2.14.2.4. ACE INHIBITORS 75 2.14.2.5. AT, RECEPTOR
BLOCKERS 76 2.14.2.6. POST-SYNAPTIC ALPHA-1 BLOCKERS 77 2.14.2.7.
CENTRALLY ACTING ANTIHYPERTENSIVES 77 2.14.2.8. THE RENIN INHIBITOR 78
2.14.3. THE TROUGH-TO-PEAK RATIO 78 2.14.4. DIFFERENTIATED TREATMENT OF
HYPERTENSION (ESH / ESC 2007) 79 2.15. RATIONAL COMBINATIONS 79 2.15.1.
ADDITIVE BLOOD PRESSURE-LOWERING EFFECT 79 2.15.2. INCREASE IN THE
RESPONDER RATE AS A RESULT OF A COMBINATION 80 2.15.3. ARE FIXED
COMBINATIONS SENSIBLE? 80 2.15.4. TREATMENT OF HYPERTENSION IN HIGH-RISK
PATIENTS 80 2.16. AIMS OF THE TREATMENT OF HYPERTENSION TODAY 81 2.17.
NON-PHARMACOLOGICAL THERAPEUTIC MEASURES 81 2.17.1. DIET 81 2.17.2.
LOW-SALT DIET 81 2.17.3 8 CONTENTS 3.5. THE 2004 NCEP (ATP III)
GUIDELINES 96 3.6. THE SITUATION IN DIABETICS 97 3.6.1 . LIPID TARGETS
FOR TREATMENT 97 3.6.2. THE CARDS STUDY 97 3.7. HMG-COA REDUCIASE
INHIBITORS IN HYPERTENSIVE PATIENTS 98 3.7.1 . THE ASCOT-LLA STUDY 98
3.7.2. THE ALLHAT LIPID ARM 99 3.8. STATINS AND CRP, THE JUPITER STUDY
100 3.9. SUMMARY 101 3.10. REFERENCES 101 TREATMENT IN STABLE CAD AND
POSTINFARCT PATIENTS 103 4.1. TREATMENT STRATEGIES IN CAD 103 4.2.
TREATMENT PRIORITIES DEPENDING ON THE WAY CAD PRESENTS 103 4.2.1.
CHRONIC STABLE CAD 103 4.2.2. UNSTABLE ANGINA 104 4.2.3. ACUTE
MYOCARDIAL INFARCTION 104 4.2.4. AFTER CABG OR PTCA 104 4.2.5. CAD
PATIENTS WITH VENTRICULAR ARRHYTHMIAS 104 4.2.6. SUMMARY 104 4.3.
NITRATES AND OTHER ANTIANGINAL AGENTS 104 4.3.1. DO NITRATES PROLONG
SURVIVAL IN CAD? 104 4.3.1.1. THE ISIS^I STUDY 105 4.3.1.2. THE GISSI-3
STUDY 105 4.3.1.3. THE META-ANALYSIS IN ISIS-4 105 4.3.1.4. NITRATES IN
SECONDARY PREVENTION 106 4.3.2. MOLSIDOMINE 106 4.3.2.1. THE ESPRIM
STUDY 106 4.3.2.2. THE ACCORD STUDY 106 4.3.3. TRAPIDIL 106 4.3.3.1. THE
STARC STUDY 106 4.3.4. POTASSIUM CHANNEL OPENERS (NICORANDIL) 106
4.3.4.1. THE IONA STUDY 107 4.3.5 CONTENTS 9 4.4.5. DO ALL BETA-BLOCKERS
HAVE A SECONDARY PREVENTION EFFECT? 113 4.4.6. CAN BETA-BLOCKERS BE USED
FOR SECONDARY PREVENTION IN CAD WITHOUT INFARCTION? 113 4.4.6.1.
BETA-BLOCKER STUDIES IN CAD WITHOUT INFARCTION 113 4.4.6.2. PROGNOSIS OF
MYOCARDIAL INFARCTION ON BETA-BLOCKERS 113 4.4.7. BETA-BLOCKERS IN HEART
FAILURE 113 4.4.8. THIRD-GENERATION BETA-BLOCKERS 114 4.4.9.
BETA-BLOCKERS IN LV DYSFUNCTION AFTER INFARCTION, THE CAPRICORN STUDY
114 4.4.10. 2007 AHA/ACC GUIDELINES 115 4.4.11. SUMMARY 115 4.4.12.
REFERENCES 116 4.5. CALCIUM ANTAGONISTS 117 4.5.1. MECHANISM OF ACTION
OF CALCIUM ANTAGONISTS 117 4.5.2. DIFFERENCES BETWEEN THE CALCIUM
ANTAGONISTS 117 4.5.3. CALCIUM ANTAGONISTS IN STABLE ANGINA 117 4.5.4.
DIHYDROPYRIDINES IN POSTINFARCT PATIENTS 118 4.5.5. DILTIAZEM IN
POSTINFARCT PATIENTS 118 4.5.5.1. THE DILTIAZEM REINFARCTION STUDY 118
4.5.5.2. THE MDPIT STUDY 119 4.5.5.3. THE INTERCEPT STUDY 119 4.5.6.
VERAPAMIL IN POSTINFARCT PATIENTS 119 4.5.6.1. THE DAVIT II STUDY 119
4.5.6.2. DAVIT II STUDY VERSUS MDPIT STUDY 120 4.5.6.3. THE CRIS STUDY
120 4.5.7. HYPERTENSIVE VERSUS NORMOTENSIVE POSTINFARCT PATIENTS 120
4.5.8. THIRD-GENERATION CALCIUM ANTAGONISTS IN CAD 121 4.5.8.1.
CHARACTERISTICS OF THIRD-GENERATION CALCIUM ANTAGONISTS 121 4.5.8.2. THE
PREVENT STUDY WITH AMLODIPINE IN CAD 121 4.5.8.3. THE CAPARES STUDY WITH
AMLODIPINE AFTER PTCA 122 4.5.8.4. THE CAMELOT STUDY 122 4.5.9 10
CONTENTS 4.6.9. ACE INHIBITORS IN ASSOCIATION WITH AND AFTER CABG*THE
QUO VADIS STUDY 134 4.6.10. ACE INHIBITORS IN CAD PATIENTS WITH A LOWER
RISK 134 4.6.10.1. THE EUROPA STUDY 134 4.6.10.2. THE PEACE STUDY 135
4.6.10.3. HOPE VERSUS EUROPA VERSUS PEACE 135 4.6.10.4. THE
META-ANALYSES OF ACE INHIBITOR STUDIES WITH PRESERVED LV FUNCTION 136
4.6.11. 2006/2007 ACC/AHA GUIDELINES 136 4.6.12. SUMMARY 137 4.6.13.
REFERENCES 137 4.7. AT, RECEPTOR BLOCKERS 139 4.7.1. THE MECHANISM OF
ACTION 139 4.7.2. AT, RECEPTOR BLOCKERS AND PLEIOTROPIC EFFECTS 139
4.7.3. CLINICAL STUDIES IN CAD 140 4.7.3.1. THE OPTIMAAL STUDY 140
4.7.3.2. THE VALIANT STUDY 140 4.7.3.3. THE ONTARGET STUDY 141 4.7.3.4.
THE TRANSCEND STUDY 142 4.7.3.5. THE PROFESS STUDY 143 4.7.4.
COMBINATION OF ACE INHIBITOR PLUS AT, RECEPTOR BLOCKER 143 4.7.5.
2006/2007 ACC/AHA GUIDELINES 143 4.7.6. SUMMARY 143 4.7.7. REFERENCES
144 4.8. STATINS (HMG-COA REDUCIASE INHIBITORS) 144 4.8.1. SITUATION
BEFORE THE STATIN ERA 144 4.8.2. MECHANISM OF ACTION OF THE STATINS 145
4.8.3. A COMPARISON OF STATINS 145 4.8.3.1. PHARMACOLOGICAL DIFFERENCES
145 4.8.3.2. STATINS AND EXTENT OF LDL REDUCTION 146 4.8.4. STATINS AND
DOSE-EFFECT RELATIONSHIP 147 4.8.5. STATINS IN SECONDARY PREVENTION*THE
EVIDENCE FROM STUDIES 147 4.8.5.1. THE 4-S STUDY 147 4.8.5.2. THE CARE
STUDY 148 4.8.5.3. THE LIPID STUDY 149 4.8.5.4 CONTENTS 11 4.8.11.6.
ANTI-ATHEROSCLEROTIC EFFECTS AS A RESULT OF HMG-COA REDUCTASE INHIBITORS
160 4.8.11.7. HMG-COA INHIBITORS AND CHANGE IN THE PLAQUE 160 4.8.12.
LDL LOWERING AND CARDIAC RISK*THE GREATER THE LDL REDUCTION, THE BETTER
161 4.8.12.1. THE AVERT STUDY 161 4.8.12.2. THE REVERSAL STUDY 161
4.8.12.3. THE ASTEROID STUDY 162 4.8.12.4. THE PROVE-IT STUDY 162
4.8.12.5. THE TNT STUDY 163 4.8.12.6. THE IDEAL STUDY 163 4.8.12.7.
SHOULD STATINS BE USED IF THE LDL IS 60 MG/DL? 164 4.8.13. LDL
TREATMENT TARGETS TODAY 164 4.8.13.1. THE 2001/2004 NCEP GUIDELINES (ATP
III) 165 4.8.14. STATINS IN HIGH-RISK PATIENTS 166 4.8.14.1. THE
ASCOT-LLA STUDY 166 4.8.14.2. THE CARDS STUDY 167 4.8.15. FIBRATES IN
SECONDARY PREVENTION 167 4.8.15.1. WHAT SHOULD BE DONE IN CAD WITH AN
LDL OF ABOUT 100 MG/DL AND A LOW HDL? 167 4.8.15.2. THE BIP STUDY 168
4.8.16. 2006/2007 ACC/AHA GUIDELINES 168 4.8.17. SUMMARY 168 4.8.18.
REFERENCES 169 4.9. ANTIPLATELET AGENTS 172 4.9.1. MECHANISM OF ACTION
OF ANTIPLATELET AGENTS 172 4.9.2. ASPIRIN (ACETYLSALICYLIC ACID, ASS)
173 4.9.2.1. THE META-ANALYSIS OF THE APTS COLLABORATION IN POSTINFARCT
PATIENTS 173 4.9.2.2. ASPIRIN AFTER CABG AND PTCA 173 4.9.2.3. THE SAPAT
STUDY*ASPIRIN IN STABLE CAD 173 4.9.2.4. THE ASPIRIN DOSAGE 174 4.9.2.5.
ON THE OPTIMAL ASPIRIN DOSE 174 4.9.2.6. AN ASPIRIN REBOUND PHENOMENON?
174 4.9.2.7. ASPIRIN IN PRIMARY PREVENTION 174 4.9.2.8 12 CONTENTS
4.9.7. CURRENT GUIDELINES 181 4.9.7.1. 2007 ACC/AHA GUIDELINES 181
4.9.7.2. 2007 ESC GUIDELINES 182 4.9.7.3. 2008 ESC GUIDELINES (STEMI)
182 4.9.7.4. 2007 ACC/AHA GUIDELINES 183 4.9.7.5. 2007 ESC GUIDELINES
183 4.9.8. SUMMARY 183 4.9.9. REFERENCES 184 4.10. ANTICOAGULANTS 186
4.10.1. THE SIXTY PLUS STUDY IN THE ELDERLY 186 4.10.2. THE WARIS-1
STUDY 186 4.10.3. THE ASPECT-1 STUDY 186 4.10.4. THE ASPECT-2 STUDY 186
4.10.5. THE WARIS-2 STUDY 187 4.10.6. THE APRICOT-2 STUDY 187 4.10.7.
INDICATIONS FOR COUMARINS TODAY 187 4.10.8. ANTITHROMBOTIC TREATMENT IN
ATRIAL FIBRILLATION 188 4.10.8.1. COUMARINS VERSUS ASPIRIN IN ATRIAL
FIBRILLATION 188 4.10.8.2. ASPIRIN PLUS CLOPIDOGREL VERSUS WARFARIN*THE
ACTIVE W STUDY 188 4.10.8.3. THE ACTIVE A STUDY 189 4.10.8.4. RISK
STRATIFICATION IN ATRIAL FIBRILLATION 189 4.10.9. SUMMARY 189 4.10.10.
REFERENCES 190 4.11. ANTIHYPERTENSIVE AGENTS 190 4.11.1. HYPERTENSION
AND RISK IN CAD 190 4.11.2. THE HOPE STUDY 191 4.11.3. SUBGROUP ANALYSIS
OF THE CAD PATIENTS IN THE HOT STUDY 191 4.11.4. ISOLATED SYSTOLIC
HYPERTENSION (ISH) 192 4.11.5. THE RENAAL STUDY AND IDNT STUDY 192
4.11.6. THE INVEST STUDY 192 4.11.7. TARGET BLOOD PRESSURE VALUES IN CAD
193 4.11.8. SUMMARY 193 4.11.9. REFERENCES 193 4.12. ONNEGA-3 FATTY
ACIDS 194 4.12.1. THE GISSI PREVENTION STUDY 194 4.12.2 CONTENTS 13
UNSTABLE ANGINA PECTORIS/NON-Q-WAVE INFARCTION (NSTEMI) 203 5.1.
DEFINITION 203 5.2. THE PROGNOSIS IN UNSTABLE ANGINA/NON-Q-WAVE
INFARCTION 203 5.3. AIMS OF TREATMENT 204 5.4. NITRATES IN UNSTABLE
ANGINA/NON-Q-WAVE INFARCTION 204 5.5. BETA-BLOCKERS 204 5.6. CALCIUM
ANTAGONISTS 205 5.6.1. META-ANALYSIS BY HELD 205 5.6.2. THE HINT STUDY
205 5.6.3. THE DILTIAZEM REINFARCTION STUDY 205 5.7. ASPIRIN 205 5.8.
HEPARIN IN UNSTABLE ANGINA/NSTEMI 205 5.8.1. UNFRACTIONATED HEPARIN 205
5.8.2. LOW-MOLECULAR-WEIGHT HEPARIN 205 5.8.2.1. THE ESSENCE STUDY 205
5.8.2.2. THE TIM111* STUDY 205 5.8.2.3. THE TIM111B ESSENCE
META-ANALYSIS 206 5.8.2.4. THE INTERACT STUDY (ACC ATLANTA, MARCH 2002)
206 5.8.2.5. THE SYNERGY STUDY 206 5.8.2.6. THE A TO Z STUDY 206 5.8.3.
PENTASACCHARIDES 206 5.8.3.1. THE OASIS-5 STUDY 206 5.8.4. BIVALIRUDIN
207 5.9. GLYCOPROTEIN LLB/LLLA RECEPTOR INHIBITORS IN UNSTABLE ANGINA
207 5.9.1. THE PRISM STUDY 207 5.9.2. THE PRISM-PLUS STUDY 207 5.9.3.
THE PURSUIT STUDY 208 5.9.4. THE META-ANALYSIS OF STUDIES WITH GP
LLB/LLLA INHIBITORS 208 5.9.5. GLYCOPROTEIN LLB/LLLA RECEPTOR
INHIBITORS*DIABETICS VERSUS NON-DIABETICS 208 5.10. CLOPIDOGREL PLUS
ASPIRIN IN UNSTABLE ANGINA/NON-Q-WAVE INFARCTION 209 5.10.1 14 CONTENTS
5.14. THE IMPORTANCE OF GLYCOPROTEIN LLB/LLLA RECEPTOR INHIBITORS IN PCI
219 5.14.1. THE CAPTURE STUDY 219 5.14.2. THE RESTORE STUDY 219 5.15.
THE COMBINATION OF GP LLB/LLLA INHIBITORS, ASPIRIN, HEPARIN, CLOPIDOGREL
220 5.16. IMPROVEMENT IN PROGNOSIS IN NSTE-ACS 220 5.17. APPROACH IN
UNSTABLE ANGINA/NSTEMI (2007 ESC AND ACC/AHA GUIDELINES) 220 5.17.1.
TYPE OF THERAPEUTIC APPROACH 220 5.17.2. FOR ANTIPLATELET DRUGS 221
5.17.3. FOR HEPARIN 222 5.17.4. ON LIPID-LOWERING 222 5.17.5. TIMINGS
DURING TREATMENT OF NSTEMI-ACS 222 5.17.5.1. EARLY VERSUS DELAYED PCI
(TIMACS) 222 5.17.5.2. WHEN SHOULD EPTIFIBATIDE BE USED IN NSTEMI?
(EARLY ACS) 223 5.18. ALGORITHM IN THE CASE OF ACS*2007 ESC GUIDELINES
223 5.19. SUMMARY 223 5.20. REFERENCES 224 THE TREATMENT OF ACUTE
MYOCARDIAL INFARCTION 228 6.1. THE EFFECT OF THROMBOLYSIS 228 6.1.1. THE
ISIS-2 STUDY 228 6.1.2. THE GUSTO-I STUDY 229 6.1.3. THE META-ANALYSIS
OF THE FIBRINOLYTIC THERAPY TRIALISTS COLLABORATIVE GROUP 229 6.1.4.
PROBLEMS OF THROMBOLYTIC THERAPY IN ML 230 6.1.5. COMBINATION OF
THROMBOLYTIC AGENTS AND GP LLB/LLLA RECEPTOR INHIBITORS 230 6.2. ASPIRIN
231 6.2.1. THE ISIS-2 STUDY WITH ASPIRIN 231 6.2.1.1. THE META-ANALYSIS
OF THE ANTIPLATELET TRIALISTS COLLABORATION 231 6.3.
CIOPIDOGREL/PRASUGREL 232 6.3.1. THE CLARITY-TIMI-28 STUDY 232 6.3.2.
THE COMMIT/CCS 2 STUDY 232 6.3.3 CONTENTS 15 6.6. BETA-BLOCKERS 236
6.6.1. THE MIAMI STUDY 236 6.6.2. THE ISIS-1 STUDY 237 6.6.3. THE
META-ANALYSIS BY YUSUF 237 6.6.4. BETA-BLOCKERS IN ML IN DIABETICS 237
6.7. ACE INHIBITORS/AT, RECEPTOR BLOCKERS 238 6.7.1. THE GISSI-3 STUDY
238 6.7.2. THE ISIS-4 STUDY 238 6.7.3. THE SMILE STUDY 238 6.7.4.
SYSTEMATIC ANALYSIS OF SEVERAL ACE INHIBITOR STUDIES 239 6.7.5. AT,
RECEPTOR BLOCKERS 239 6.8. CALCIUM ANTAGONISTS 239 6.9. ANTIARRHYTHMICS
(LIDOCAINE PROPHYLAXIS) 239 6.10. PTCA IN ACUTE INFARCTION 239 6.10.1 .
IMMEDIATE PTCA VERSUS LYSIS WITH T-PA 240 6.10.2. IMMEDIATE PTCA VERSUS
LYSIS WITH T-PA IN GUSTO LIB 240 6.10.3. THE DANAMI-2 STUDY (LYSIS
VERSUS PCI) 240 6.10.4. IMMEDIATE PTCA VERSUS LYSIS IN THE LONG TERM 240
6.10.5. THE PRAGUE-2 STUDY 241 6.10.6. PTCA VERSUS PTCA PLUS STENT 241
6.10.7. PTCA VERSUS THROMBOLYSIS IN DIABETICS VERSUS NON-DIABETICS 241
6.10.8. PTCA PLUS STENT PLUS GP LLB/LLLA INHIBITOR 241 6.10.8.1. THE
ADMIRAL STUDY 241 6.10.8.2. THE CADILLAC STUDY 242 6.10.9. RESULTS OF
META-ANALYSES 242 6.10.10. RESCUE PCI/FACILITATED PCI 243 6.11. NATIONAL
DIFFERENCES IN THE HOSPITALISATION TIME 243 6.12. THE PROGNOSIS IN STEMI
243 6.1 3 16 CONTENTS 7.3. STENTS 253 7.3.1. STUDIES ON STENT
IMPLANTATION 253 7.3.1.1. BMS STENTS 253 7.3.1.2. DRUG-ELUTING STENTS
253 7.3.1.3. BMS VERSUS DES 254 7.3.1.4. SIROLIMUS VERSUS PACLITAXEL 255
7.4. PTCA VERSUS CABG 255 7.4.1. THE BARI STUDY 255 7.4.2. PTCA PLUS
STENT VERSUS BYPASS SURGERY IN MULTIVESSEL DISEASE 256 7.4.3.
META-ANALYSIS ON CABG VERSUS PCI 256 7.4.4. THE META-ANALYSIS OF 10
STUDIES 256 7.4.5. THE SYNTAX STUDY WITH DES 256 7.5. PTCA VERSUS
ATHERECTOMY 257 7.5.1. THE CAVEAT I STUDY 257 7.5.2. THE BOAT STUDY 257
7.5.3. VENOUS GRAFT STENOSIS 257 7.5.3.1. THE CAVEAT II STUDY 257
7.5.3.2. PCI IN VENOUS GRAFT STENOSIS AND GP LLB/LLLA RECEPTOR
INHIBITORS 258 7.6. TRANSMYOCARDIAL LASER REVASCULARISATION 258 7.6.1.
THE ATLANTIC STUDY 258 7.6.2. THE PACIFIC STUDY 258 7.6.3. RESULT OF A
META-ANALYSIS 258 7.7. BETA-BLOCKERS BEFORE CABG 258 7.8. PCI VERSUS
CONSERVATIVE TREATMENT IN CHRONIC STABLE CAD 258 7.8.1. THE COURAGE
STUDY 258 7.8.2. RESULT OF A META-ANALYSIS 259 7.8.3. PHARMACOLOGICAL
VERSUS DIFFERENT INTERVENTIONAL THERAPIES 259 7.8.4. THE BARI 2D STUDY
260 7.9. CORONARY ANGIOGRAPHY VERSUS FRACTIONAL FLOW RESERVE AS A
PARAMETER FOR INDICATING PCI*THE FAME STUDY 260 7.10. SURGICAL VENTRICLE
RECONSTRUCTION IN CABG*THE STICH STUDY (HYPOTHESIS 2) 261 7.11. SUMMARY
261 7.12. REFERENCES 261 TREATMENT OF CHRONIC SYSTOLIC HEART FAILURE 265
8.1 CONTENTS 17 8.3. POSITIVE INOTROPIC DRUGS 271 8.3.1. MECHANISM OF
POSITIVE INOTROPIC SUBSTANCES 271 8.3.2. DIGITALIS 271 8.3.2.1.
PHARMACOLOGICAL DATA ON CARDIAC GLYCOSIDES 272 8.3.2.2. CLINICAL STUDIES
272 8.3.2.3. DIGITALIS AFTER INFARCTION IN SYMPTOMATIC HEART FAILURE 273
8.3.2.4. 2008 ESC GUIDELINES 273 8.3.2.5. SUMMARY (DIGITALIS) 274 8.3.3.
DOBUTAMINE 274 8.3.4. PHOSPHODIESTERASE INHIBITORS 274 8.3.5. XAMOTEROL
275 8.3.6. VESNARINONE 275 8.3.7. IBOPAMINE 275 8.3.8. PIMOBENDAN 275
8.3.9. LEVOSIMENDAN 276 8.3.10. SUMMARY (POSITIVE INOTROPIC AGENTS) 276
8.3.11. REFERENCES 276 8.4. ACE INHIBITORS 277 8.4.1. PATHOPHYSIOLOGICAL
BASIS OF ACE INHIBITOR TREATMENT 277 8.4.2. MECHANISM OF ACTION 278
8.4.3. PHARMACOLOGICAL DATA ON ACE INHIBITORS 279 8.4.4. CLINICAL USE OF
ACE INHIBITORS 279 8.4.4.1. GRADUAL UPTITRATION OF DOSAGE 279 8.4.4.2.
RIGHT DOSAGE 279 8.4.4.3. DOSES IN THE INTERVENTION STUDIES 280 8.4.4.4.
DOSAGE RECOMMENDATIONS OF THE MANUFACTURERS 280 8.4.4.5. THE ATLAS STUDY
280 8.4.5. KIDNEY AND HEART FAILURE 280 8.4.6. ACE INHIBITORS AND NSAIDS
281 8.4.6.1. ACE INHIBITORS AND ASPIRIN 281 8.4.7. CLINICAL HEART
FAILURE STUDIES WITH ACE INHIBITORS 282 8.4.7.1. THE CONSENSUS I STUDY
282 8.4.7.2. THE V-HEFT II STUDY 282 8.4.7.3. THE SOLVD TREATMENT ARM
282 8.4.7.4. THE SOLVD PREVENTION ARM 283 8.4.7.5 18 CONTENTS 8.6. OTHER
VASODILATORS 295 8.6.1. HYDRALAZINE 295 8.6.1.1. THE V-HEFT I STUDY 295
8.6.1.2. THE V-HEFT II STUDY 296 8.6.1.3. THE A-HEFT STUDY 296 8.6.2.
ALPHA-1 BLOCKERS 2% 8.6.3. NITRATES 297 8.6.4. EPOPROSTENOL 297 8.6.5.
FLOSEQUINAN 297 8.6.6. SUMMARY (VASODILATORS) 297 8.6.7. REFERENCES 297
8.7. CALCIUM ANTAGONISTS 298 8.7.1. MECHANISM OF ACTION 298 8.7.2.
CLINICAL STUDIES IN HEART FAILURE 298 8.7.2.1. THE V-HEFT III STUDY 298
8.7.2.2. THE PRAISE I STUDY 298 8.7.2.3. THE PRAISE II STUDY 299
8.7.2.4. THE MACH I STUDY 299 8.7.3. SUMMARY (CALCIUM ANTAGONISTS) 299
8.7.4. REFERENCES 299 8.8. BETA-BLOCKERS 299 8.8.1. CLINICAL BACKGROUND
300 8.8.2. PATHOPHYSIOLOGICAL BACKGROUND 300 8.8.3. BETA-BLOCKERS*FROM
CONTRAINDICATION TO INDICATION 301 8.8.4. POSSIBLE MECHANISMS OF
BETA-BLOCKERS N HEART FAILURE 302 8.8.5. TYPE OF BETA-BLOCKER AND
NEGATIVE NOTROPISM 303 8.8.6. CLINICAL STUDIES WITH BETA-BLOCKERS IN
HEART FAILURE 303 8.8.6.1. THE US CARVEDILOL STUDY 303 8.8.6.2. THE
CIBISII STUDY 304 8.8.6.3. THE MERIT-HF STUDY 304 8.8.6.4. COMPARISON OF
THE RESULTS OF THE THREE LARGE BETA-BLOCKER STUDIES IN NYHA CLASS 11/111
HEART FAILURE 305 8.8.7. BETA-BLOCKERS IN NYHA CLASS IV? 305 8.8.7.1.
EVIDENCE BEFORE THE COPERNICUS STUDY 305 8.8.7.2. THE COPERNICUS STUDY
306 8.8.8. BETA-BLOCKERS IN ASYMPTOMATIC LV DYSFUNCTION? 306 8.8.8.1
CONTENTS 19 8.9. ALDOSTERONE ANTAGONISTS IN HEART FAILURE 314 8.9.1. THE
RATIONALE OF TREATMENT WITH ALDOSTERONE ANTAGONISTS 315 8.9.2.
ALDOSTERONE AND SPIRONOLACTONE EFFECTS 315 8.9.3. THE RALES STUDY 315
8.9.4. INCREASED INCIDENCE OF HYPERKALAEMIA AFTER PUBLICATION OF THE
RALES STUDY 316 8.9.5. ALDOSTERONE ANTAGONISTS IN POSTINFARCTION HEART
FAILURE 316 8.9.5.1. THE RATIONALE 316 8.9.5.2. ALDOSTERONE, A PREDICTOR
OF PROGNOSIS IN ACUTE MYOCARDIAL INFARCTION 316 8.9.5.3. EPLERENONE IN
THE EPHESUS STUDY 317 8.9.6. WHEN SHOULD ALDOSTERONE ANTAGONISTS BE
USED? 318 8.9.7. SUMMARY (ALDOSTERONE ANTAGONISTS) 318 8.9.8. REFERENCES
318 8.10. OMEGA-3 FATTY ACIDS 319 8.10.1. THE GISSI-HF STUDY 319 8.10.2.
REFERENCES 320 8.11. ANTICOAGULANT DRUGS 320 8.11.1. THE INCIDENCE OF
EMBOLISM IN CONTROLLED STUDIES 320 8.11.2. ASPIRIN IN HEART FAILURE 320
8.11.3. ANTICOAGULANTS IN HEART FAILURE 321 8.11.4. HEPARIN 321 8.11.5.
CLOPIDOGREL 321 8.11.5.1. THE WATCH STUDY 321 8.11.6. WARFARIN VERSUS
ASPIRIN PLUS CLOPIDOGREL 322 8.11.7. ACC/AHA/ESC GUIDELINES ON ATRIAL
FIBRILLATION AND COUMARIN TREATMENT 322 8.11.8. SUMMARY 322 8.11.9.
REFERENCES 323 8.12. EVIDENCE-BASED TREATMENT IN SYSTOLIC HEART
FAILURE*ALGORITHMS 323 8.12.1. ALGORITHMS IN SYSTOLIC HEART FAILURE 323
8.12.2. DIASTOLIC HEART FAILURE 324 8.12.3. CURRENT 2009 ACC/AHA
GUIDELINES 324 8.12.4. REFERENCES 325 ANTIARRHYTHMI 20 CONTENTS 9.6.3.
THE DIAMOND STUDY 331 9.6.4. DRONEDARONE 331 9.6.4.1. DRONEDARONE IN
HEART FAILURE 332 9.6.4.2. THE ATHENA STUDY 332 9.6.5. HEART FAILURE
THERAPY AND ATRIAL FIBRILLATION 333 9.6.6. RATE CONTROL VERSUS RHYTHM
CONTROL IN ATRIAL FIBRILLATION 333 9.6.6.1. THE AFFIRM STUDY 333 9.6.7.
THE RACE STUDY 334 9.7. SUMMARY 334 9.8. REFERENCES 335 ICD, CRT,
CARDIAC PACEMAKERS 337 10.1. THE IMPLANTABLE DEFIBRILLATOR (ICD) 337
10.1.1. THE AVID STUDY IN SUSTAINED VENTRICULAR TACHYCARDIA 337 10.1.2.
THE CASH STUDY 337 10.1.3. THE C1DS STUDY 337 10.1.4. THE MADITI STUDY
IN NON-SUSTAINED VENTRICULAR TACHYCARDIA 338 10.1.5. THE CABG-PATCH
STUDY 338 10.1.6. THE META-ANALYSIS OF THE ICD STUDIES 338 10.1.7. THE
MADIT II STUDY 339 10.1.8. THE SCD-HEFT STUDY 340 10.1.9. IN THE CASE OF
ICD, WIR OR DDDR*DAVID STUDY 340 10.1.10. ICD IN DILATED
CARDIOMYOPATHY*THE DEFINITE STUDY 341 10.1.11. WHEN SHOULD ICD BE USED
AFTER MYOCARDIAL INFARCTION? 341 10.1.12. INDICATION FOR PROPHYLACTIC
ICD 342 10.2. RESYNCHRONISATION THERAPY (CRT) 342 10.2.1. THE MUSTIC
STUDY 343 10.2.2. THE MIRACLE STUDY 343 10.2.3. THE META-ANALYSIS OF THE
RESYNCHRONISATION STUDIES TO DATE 343 10.2.4. THE COMPANION STUDY 344
10.2.5. THE CARE-HF STUDY 344 10.2.6. CRT IN ATRIAL FIBRILLATION? 345
10.2.7. INDICATION FOR CRT 345 10.3. PROGRAMMED STIMULATION FOR RISK
IDENTIFICATION 346 10.4
|
| any_adam_object | 1 |
| author | Strödter, Dietrich Santosa, Frans |
| author_GND | (DE-588)108228061 (DE-588)113400969 |
| author_facet | Strödter, Dietrich Santosa, Frans |
| author_role | aut aut |
| author_sort | Strödter, Dietrich |
| author_variant | d s ds f s fs |
| building | Verbundindex |
| bvnumber | BV035773020 |
| ctrlnum | (OCoLC)506487518 (DE-599)GBV609690949 |
| dewey-full | 616.1206 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.1206 |
| dewey-search | 616.1206 |
| dewey-sort | 3616.1206 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| edition | 1. ed. |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01607nam a2200409 c 4500</leader><controlfield tag="001">BV035773020</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20091016 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">091015s2009 ad|| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783837411737</subfield><subfield code="9">978-3-8374-1173-7</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781848151505</subfield><subfield code="9">978-1-8481-5150-5</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)506487518</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)GBV609690949</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="1" ind2=" "><subfield code="a">eng</subfield><subfield code="h">ger</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-19</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.1206</subfield><subfield code="2">22/ger</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Strödter, Dietrich</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)108228061</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Evidence based treatment in cardiology</subfield><subfield code="c">[Dietrich Strödter ; Frans Santosa]</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">1. ed.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Bremen [u.a.]</subfield><subfield code="b">UNI-MED-Verl.</subfield><subfield code="c">2009</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">358 S.</subfield><subfield code="b">Ill., zahlr. graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">UNI-MED science</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Herzkrankheit</subfield><subfield code="0">(DE-588)4024663-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Evidenz-basierte Medizin</subfield><subfield code="0">(DE-588)4543414-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Herzkrankheit</subfield><subfield code="0">(DE-588)4024663-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Evidenz-basierte Medizin</subfield><subfield code="0">(DE-588)4543414-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Santosa, Frans</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)113400969</subfield><subfield code="4">aut</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=018632680&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-018632680</subfield></datafield></record></collection> |
| id | DE-604.BV035773020 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T22:04:12Z |
| institution | BVB |
| isbn | 9783837411737 9781848151505 |
| language | English German |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-018632680 |
| oclc_num | 506487518 |
| open_access_boolean | |
| owner | DE-19 DE-BY-UBM |
| owner_facet | DE-19 DE-BY-UBM |
| physical | 358 S. Ill., zahlr. graph. Darst. |
| publishDate | 2009 |
| publishDateSearch | 2009 |
| publishDateSort | 2009 |
| publisher | UNI-MED-Verl. |
| record_format | marc |
| series2 | UNI-MED science |
| spelling | Strödter, Dietrich Verfasser (DE-588)108228061 aut Evidence based treatment in cardiology [Dietrich Strödter ; Frans Santosa] 1. ed. Bremen [u.a.] UNI-MED-Verl. 2009 358 S. Ill., zahlr. graph. Darst. txt rdacontent n rdamedia nc rdacarrier UNI-MED science Therapie (DE-588)4059798-2 gnd rswk-swf Herzkrankheit (DE-588)4024663-2 gnd rswk-swf Evidenz-basierte Medizin (DE-588)4543414-1 gnd rswk-swf Herzkrankheit (DE-588)4024663-2 s Therapie (DE-588)4059798-2 s Evidenz-basierte Medizin (DE-588)4543414-1 s DE-604 Santosa, Frans Verfasser (DE-588)113400969 aut DNB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=018632680&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Strödter, Dietrich Santosa, Frans Evidence based treatment in cardiology Therapie (DE-588)4059798-2 gnd Herzkrankheit (DE-588)4024663-2 gnd Evidenz-basierte Medizin (DE-588)4543414-1 gnd |
| subject_GND | (DE-588)4059798-2 (DE-588)4024663-2 (DE-588)4543414-1 |
| title | Evidence based treatment in cardiology |
| title_auth | Evidence based treatment in cardiology |
| title_exact_search | Evidence based treatment in cardiology |
| title_full | Evidence based treatment in cardiology [Dietrich Strödter ; Frans Santosa] |
| title_fullStr | Evidence based treatment in cardiology [Dietrich Strödter ; Frans Santosa] |
| title_full_unstemmed | Evidence based treatment in cardiology [Dietrich Strödter ; Frans Santosa] |
| title_short | Evidence based treatment in cardiology |
| title_sort | evidence based treatment in cardiology |
| topic | Therapie (DE-588)4059798-2 gnd Herzkrankheit (DE-588)4024663-2 gnd Evidenz-basierte Medizin (DE-588)4543414-1 gnd |
| topic_facet | Therapie Herzkrankheit Evidenz-basierte Medizin |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=018632680&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT strodterdietrich evidencebasedtreatmentincardiology AT santosafrans evidencebasedtreatmentincardiology |